Prof. Lu Si 斯璐
Chief Physician, Professor
Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical focus on melanoma, skin tumors, renal cell carcinoma, bladder cancer, and urothelial carcinoma.
Dr. Si is a Chief Physician and Professor at Peking University Cancer Hospital. Research focuses on melanoma and advanced genitourinary tumors. Dr. Si serves as Academic Secretary of the Asian Melanoma Alliance and contributed to six editions of the Chinese Melanoma Diagnosis and Treatment Guidelines. Awards include the Chinese Medical Association Science and Technology Progress Award.
Professional roles
- Vice Chair, Melanoma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Nervous System Tumor Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Rare Tumor Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Immunotherapy Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Si Lu). Papers usually list the name as Lu Si or Si L.
Selected publications
169 papers on PubMed matched by name and affiliation; 41 as first or senior author since 2016. Most recent first- or senior-author papers:
- Future Oncol, 2026 (senior author): Treatment patterns and characteristics of Chinese patients with advanced or resectable melanoma: a multicenter retrospective study. PubMed 42968552
- Exp Hematol Oncol, 2026 (senior author): Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy. PubMed 42226303
- Nat Commun, 2026 (senior author): A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma. PubMed 42140948
- Expert Opin Biol Ther, 2026 (senior author): Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications. PubMed 42056853
- Cancer Sci, 2025 (senior author): CNDP1 Overexpression by Promoter Hypomethylation Predicts Poor Prognosis and Immunotherapy Response in Mucosal Melanoma. PubMed 40133062
- Cancer Invest, 2025 (senior author): Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis. PubMed 40405688
- Cancer Manag Res, 2025 (senior author): Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma. PubMed 40331053
- J Genet Genomics, 2025 (senior author): Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian. PubMed 39798666
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion